wherein the PV infection is characterised by the presence of epithelial lesions.

3. (Amended) [A] The method of treatment [as claimed in] according to Claim 2, wherein the epithilial lesions are selected from the group consisting of palmar warts, planter warts, ano-genital warts, flat and planar warts of the skin and muscosal surfaces, CIN, equine sarcoid and replicating or vegetative PV infection.

4 (Amended) [A] The method of treatment [as claimed in] according to Claim 3, wherein the [PV infection is] epithelial lesions are genital warts caused by HPV 6, 11, 34, 39, 41 [-44 and 51-] 42, 43, 44, 51, 52, 53, 54, or 55.

Sub B2

5. (Amended) [A] The method of treatment [as claimed in] according to Claim 4, wherein the genital warts are caused by HPV 6 [and] or HPV 11.

6. (Amended) A method of [treatment as claimed in any preceding claim wherein the VLPs are produced by] producing a PV VLP comprising: (a) cloning [the] one or more PV [L1 gene] VLP genes into a [suitable] vector and (b) expressing the [corresponding conformational coding sequence for L1] one or more PV VLP genes in an eukaryotic cell transduced by the vector.

B3

Sub

7. (Amended) [A] The method [of treatment as claimed in] according to Claims 1-5 [wherein the VLPs are produced by], further comprising: cloning the PV L1 [and] or PV L2 gene[s] into a [suitable] vector and expressing the [corresponding conformational coding sequence for L1 and L2] PV L1 or PV L2 gene in [an eukaryotic] a host cell [transduced by the vector].

8. (Amended) [A] The method [as claimed in] according to Claim 6 [or 7], wherein the one or more PV VLP genes comprise (i) a PV L1 VLP gene or [L1 and L2 genes are inserted into] (ii) a PV L1 VLP gene and a PV L2 VLP gene, wherein the vector is an expression vector [containing flanking sequences to form a gene construct and the resulting recombinant DNA is co-transfected with wild type baculovirus DNA into], wherein the host cell is a cell from a permissive cell line.

9. (Amended) [A] The method [as claimed in] according to Claim 6 [or 7] , wherein the permissive cell line is a Sf9 insect cell[s] line and the expression vector is a baculovirus expression vector.

10. (Amended) [A] The method [as claimed in] according to Claim 8 , wherein the permissive cell line is a procaryotic cell line.

11. (Amended) [A] The method [as claimed in any preceding claim] according to Claim 1, wherein the concentration of PV L1 VLPs or PV L1 VLPs and PV L2 VLPs administered to the patient is 0.5-20 μg.

12. (Amended) [A] The method [as claimed in] according to Claim 11 , wherein the concentration is 1-10 μg.

13. (Amended) [A] The method [of treatment as claimed in] according to Claim 11 or 12 , wherein [dosages of PV VLPs are given] the composition is administered 3-6 times over a period of 8-1 6 weeks.

14. (Amended) [A] The method [of treatment as claimed in] according to Claim 11 , wherein [dosages of PV VLPs are} the composition is administered 3-6 times over a period of 2-4 weeks.

15. (Amended) A method of immunization against HPV11 infection[s by administration of] comprising administering HPV6 VLPs to a patient.

16. (Amended) [A] The method [as claimed in] according to Claim 15 , wherein the HPV6 VLPs are HPV6b VLPs [are administered to the patient] .

17. (Amended) [A] The method [as claimed in] according to Claim 15 or 16 , wherein the concentration of the HPV6 VLPs are 0.5-20 μg.

18. (Amended) [A] The method [as claimed in] according to Claim 17 , wherein the concentration of the HPV6 VLPs are 1-10 μg.

19. (Amended) [A] The method [as claimed in] according to Claim 17 [or 18] , wherein [dosages of] the HPV6 VLPs are [given] administered 3-6 times over a ~~period~~ of 8-16 weeks.

20. (Amended) [A] The method [as claimed in] according to Claim ~~17 [or~~ 18] , wherein [dosages of] the HPV6 VLPs are [given] administered 3-6 times over a period of 24 weeks.

21. (Amended) A method of immunization against HPV6 infections [by administration of] comprising adiministering HPV11 VLPs to a patient.

22. (Amended) [A] The method [of immunization as claimed in] according to Claim 21 , wherein the concentration of the HPV11 VLPs is 0.5-20 μg.

23. (Amended) [A] The method [of immunization as claimed in] according to Claim 22 , wherein the concentration of the HPV11 VLPs is 1-10 μg.

24. (Amended) [A] The method [of immunization as claimed in] according to Claim 22 or 23 , wherein [dosages of] the HPV11 VLPs are [given] administered 3-6 times over a ~~period~~ of 8-16 weeks.

25. (Amended) [A] method [of immunization as claimed in] according to Claim 22 or 23 , wherein [dosages of] the HPV11 VLPs are [given] administered 3-6 times over a period of 2-4 weeks.

26. (Amended) A method of treatment of an existing [PV] papillomavirus infection [which includes the step of administration of PV] comprising administering papillomavirus VLPs without adjuvant to a patient suffering from the [PV infections] papillomavirus infection .

27. (Amended) [A] The method [of treatment as claimed in] according to Claim [27] 26, wherein the [PV] papillomavirus VLPs are chimeric.

28. (Amended) [A] The method [of treatment as claimed in] according to Claim 26 ,

wherein the [PV] papillomavirus VLPs comprise E protein.

29. (Amended) [A] The method [of treatment as claimed in] according to Claim 1, wherein the [PV VLPs include administering] composition further comprises an adjuvant.

30. (Amended) [A] The method [of treatment as claimed in] according to Claim 29, wherein the adjuvant is one that induces cellular responses.

31. (Amended) [A] The method [of treatment as claimed in] according to Claim 30, wherein the adjuvant[s are] is selected from the group consisting of (1) lipid A and derivatives, (2) Quillaia saponins and derivatives, (3) mycobacteria and components or derivatives therefrom [and], (4) IL 12, GMCSF, other Th1 inducting cytokines and (5) ozidized mannan and analogues thereof.

Please add the following new claim:

Sub 32-~~32~~. (New) The method according to Claim ~~1~~, wherein the composition lacks an adjuvant.-

REMARKS

The Amendments

There are two Claim 13's, the first Claim 13 is cancelled.

Claims 1-31 are amended to conform claim language to U.S. patent law. Support for Claims 1-31 is found, for example, in Claims 1-31 as originally filed.

Support for new Claim 32 is found, for example, in first Claim 13 as originally filed.

No new matter is added in any of the above amendments and the Examiner is respectfully requested to enter the amendments.

Respectfully submitted,

Date: August 14, 2001

Albert P. Halluin (Reg. No. 25,227)
Robin C. Chiang (Reg. No. 46,619)

HOWREY SIMON ARNOLD & WHITE, LLP
Box 34
301 Ravenswoods Avenue
Menlo Park, CA 95025
(650) 463-8109